Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today announced that it has completed a $21M Series D financing led by BDC Capital and SR One with participation by all current investors. Thrasos’ Board of Directors will be expanded with the addition of Ela Borenstein, Managing Partner at BDC Capital Healthcare Venture Fund.
{iframe}http://www.businesswire.com/news/home/20150331005260/en/Thrasos-Secures-21-Million-Complete-Phase-2{/iframe}